nad has been researched along with sorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, J; Mu, X; Wang, Z; Yang, Q; Zhao, Y | 1 |
| Chang, S; Chen, F; Li, G; Li, X; Liu, Q; Meng, F; Sun, L; Wang, H; Zhang, J | 1 |
2 other study(ies) available for nad and sorafenib
| Article | Year |
|---|---|
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicumarol; Female; Glutathione; Humans; Hypoxia; Micelles; NAD; NADP; Nitroimidazoles; Oxygen; Phosphates; Polyethylene Glycols; Polymers; Quinones; Sorafenib; Thioredoxins | 2022 |
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.
Topics: Animals; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; NAD; NF-E2-Related Factor 2; Oxidoreductases; Quinones; Rabbits; Sorafenib | 2023 |